VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 16, 2017) - Vinergy Resources Ltd. ("Vinergy" or the "Company") (CSE:VIN)(OTCQB:VNNYF) in conjunction with its proposed acquisition of MJ BioPharma (announced December 14, 2016) is pleased to announce that, as a part of the Company's strategy to develop a lab for research and development products that test and identify specific cannabinoid isolates for targeted therapeutic purposes, it has appointed John Simon to the Company's Scientific Advisory Board (SAB).

John has a Bachelor of Science from the University of Alberta, is a senior member of the American Society for Quality, a Certified Quality Auditor (CQA), a Registered Quality Assurance Professional in Good Laboratory Practice (RQAP-GLP) and maintains Regulatory Affairs Certification (RAC) through the Regulatory Affairs Professional Society.

John has held various management positions in Quality Assurance and Regulatory Affairs and has worked as a consultant supporting clients in the medical device, pharmaceutical, biotechnology and natural health product industries since 2004. He has been directly involved in Federal Drug Administration (FDA) and Health Canada audits of medical device manufacturers, drug manufacturers, testing facilities, and clinical sites. He has experience with submissions to the FDA and Health Canada.

Through John's consultancy practice he assists companies with both site licenses and product licenses. He has helped companies obtain, renew and maintain in good standing Drug Establishment Licenses (DEL); Medical Device Establishment Licenses (MDEL); Natural and Non-prescription Site Licenses (NNHPD); and Licenses to Cultivate and Distribute under the Marihuana for Medical Purposes Regulations (MMPR) (now under the ACMPR).

John also works in creating quality systems to support ISO certification for various clients (ISO 17025, ISO 13485 and ISO 9001). John consults to groups in the creation of specifications, batch records and procedures to support the design and development of a variety of products including cosmetics, natural health products, medical devices, biologics, pharmaceuticals and controlled substances.

"With John's substantial background in QA and regulatory affairs specific to drug development and the cannabis industry he will be a key asset in driving our cannabis product and technology initiatives," said Mr.Kent Deuters, CEO of MJ Biopharma.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Vinergy Resources Ltd.

Glen Macdonald, Director

Cautionary Statement Regarding "Forward-Looking" Information

The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information. Information pertaining to the Target has been provided by the Target.